Abstract
Of the only 20% of patients (pts) with resectable pancreatic ductal adenocarcinoma (PDA), overall survival (OS) remains low as cancer recurs in 80% of cases within 2 years of surgery. Epigenetic modulators such as 5-azacitidine (CC-486) may reactivate tumor suppressor genes, delay recurrence, and sensitize PDA to future chemotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
